 |
3 Products |  |
253 Diseases | | 3 Products |
|
45 Trials |  |
1655 News |  |
| «12...678910111213141516...2122» |
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal: Effect of Ketone Body β-Hydroxybutyrate to Attenuate Inflammation-Induced Mitochondrial Oxidative Stress in Vascular Endothelial Cells (Pubmed Central) - Nov 30, 2021
In addition, ITSA1 treatment could completely offset the antioxidant and mitochondrial protective effects of β-OHB, and these stated effects were still maintained after Entinostat treatment. The ketone body β-OHB attenuates the mitochondrial oxidative stress of vascular endothelial cells through activating the antioxidant pathway and inhibiting histone deacetylase activity.
- | Farydak (panobinostat) / Novartis
Journal, Epigenetic controller: Class I and II Histone Deacetylase Inhibitor LBH589 Promotes Endocrine Differentiation in Bone Marrow Derived Human Mesenchymal Stem Cells and Suppresses Uncontrolled Proliferation. (Pubmed Central) - Nov 29, 2021
The broad spectrum inhibitor of class I and class II histone deacetylases LBH589 upregulated the expression of these transcription factors in a significant way, whereas addition of selective class I histone deacetylase inhibitors MS-275 and MGCD0103 did not result in significant changes in gene expression.In conclusion, we deliver evidence that a combined class I and II histone deacetylase inhibition is able to modulate the transcripts of differentiation markers of mesenchymal stem cells. The treatment holds the capability to facilitate endocrine differentiation in future approaches to replace endocrine cells by stem cell therapy.
- entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
EPIGENETIC MODULATION OF NK CELLS TO IMPROVE TUMOR TRAFFICKING AND ENHANCE THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA ([VIRTUAL]) - Nov 26, 2021 - Abstract #CTOS2021CTOS_246;
It also increases H3 and H4 acetylation suggesting transcriptional activation of the immune-related genes that contribute to NK cell increased cytolytic function. Pre-treatment of NK cells with MS-275 enhances NK cell therapeutic efficacy.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal, Epigenetic controller: Investigating binding tendency, stability of Sulforaphane-N-acetyl cysteine in the active site of histone deacetylase 2 (HDAC2) and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell based assays. (Pubmed Central) - Nov 25, 2021
Moreover, double mutant of HDAC2 was generated and the binding orientation and interaction of SFN-NAC was explored in this state. On the whole this study showed and explained the comparatively higher binding affinity of entinostat for HDAC2 and its wide spectrum cytotoxicity than SFN-NAC.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal: HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis. (Pubmed Central) - Nov 17, 2021
We also used MS-275 to inhibit HDAC1 function in rats exposed to ischemic insult...Additionally, HDAC1 inhibition deteriorated the behavioral outcomes of rats with ischemic insult. Overall, our findings demonstrate that HDAC1 participates in ischemic pathogenesis in the brain and possesses potential for use as a therapeutic target.
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Metastases: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (clinicaltrials.gov) - Nov 16, 2021
P3, N=608, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Overall, our findings demonstrate that HDAC1 participates in ischemic pathogenesis in the brain and possesses potential for use as a therapeutic target. Trial completion date: Jan 2021 --> Oct 2028
- | ipatasertib (RG7440) / Roche, Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date: MORPHEUS: A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (clinicaltrials.gov) - Nov 16, 2021
P1/2, N=126, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2021 --> Oct 2028 Trial completion date: Mar 2024 --> Aug 2023
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Surgery: NRG-GY011: Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer (clinicaltrials.gov) - Nov 16, 2021
P1, N=50, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2024 --> Aug 2023 Trial completion date: Mar 2020 --> Mar 2021
- | azacitidine / Generic mfg., decitabine / Generic mfg.
Journal: HeLa TI cell-based assay as a new approach to screen for chemicals able to reactivate the expression of epigenetically silenced genes. (Pubmed Central) - Nov 12, 2021
Studying the additional metabolic activation of xenobiotics, we surprisingly found that the rat liver S9 fraction, which has been widely used for xenobiotic activation in genotoxicity tests, reactivated epigenetically silenced genes. Applying the HeLa TI system, we show that N-nitrosodiphenylamine and N-nitrosodimethylamine reactivate epigenetically silenced genes, probably by affecting DNA methylation.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal, Tumor-specific neoantigens: Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. (Pubmed Central) - Nov 10, 2021
Finally, combination treatment with anti-PD-1 and entinostat led to complete responses and conferred long-term immunologic memory. Our work defines a tumor cell-autonomous mechanism of action for entinostat and a strong preclinical rationale for the combined use of entinostat and PD-1 blockade in bladder cancer.
- SNDX-5613 / Syndax Pharma
Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5018;
These preclinical findings highlight the molecular correlates of anti-AML efficacy of SNDX-50469 or SNDX-5613. They also demonstrate greater in vitro and in vivo efficacy of SNDX-5613-based combinations with inhibitors of BCL2, BET proteins and CDK6 against AML harboring MLL1-FP or NPM1c.
- Jakafi oral (ruxolitinib) / Novartis, Incyte, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
The High Mobility Group A1 Chromatin Regulator Drives Immune Evasion during MPN Progression By Repressing Genes Involved in Antigen Presentation and Immune Attack (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4179;
Most importantly, HMGA1 immune evasion networks are dysregulated in human MPN and can be targeted by HDACi therapy. Together, our studies reveal a new paradigm whereby HMGA1 down-regulates MHC antigens during MPN progression, suggesting that targeting HMGA1 networks could activate an immune attack and prevent MPN progression.
- Keytruda (pembrolizumab) / Merck (MSD), entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL) (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4077;
Conclusions Interim results following stage I of this phase 2 trial demonstrates a 12-month PFS rate of 74%, meeting the primary endpoint of the study and justifying continued investigation of the combination of PEM and ENT. In this heavily pretreated patient population, responses were seen in the majority of patients despite prior exposure to anti-PD-1 agents.
- VTP-50469 / Syndax Pharma
The Menin-MLL1 Interaction Is a Molecular Dependency in NUP98-Rearranged AML (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3827;
Using mouse leukemia cell lines driven by NUP98-HOXA9 and NUP98-JARID1A fusion oncoproteins, we demonstrate that NUP98-fusion driven leukemia is sensitive to the Menin-MLL1 inhibitor VTP50469, with an IC50 similar to what we have previously reported for MLL -rearranged and NPM1c leukemia cells...Gene expression analysis revealed that Menin-MLL1 inhibition simultaneously suppresses a pro-leukemogenic gene expression program, including downregulation of the HOXA cluster, and upregulates tissue-specific markers of differentiation. These preclinical results suggest that Menin-MLL1 inhibition may represent a rational, targeted therapy for patients with NUP98 -rearranged leukemias.
- SNDX-5613 / Syndax Pharma
Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101) (GWCC - Georgia Ballroom 1-3) - Nov 5, 2021 - Abstract #ASH2021ASH_2187;
Two dose levels in each arm met the prespecified criteria for RP2D. Ph 2 expansion includes cohorts of pts with MLLr AML, MLLr ALL, and mNPM1 AML.
- axatilamab (SNDX-6352) / Syndax Pharma, Incyte
Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment (GWCC - B304-B305, Level 3) - Nov 5, 2021 - Abstract #ASH2021ASH_1575;
Data from this Ph 1/2 study demonstrate the safety and clinical activity of Axa in heavily pre-treated pts with active cGVHD, particularly those with fibrotic manifestations. A randomized pivotal study (AGAVE-201) has started enrolling a similar pt population, evaluating doses of 1 mg/kg Q2W and 3mg/kg Q4W, along with a lower dose of 0.3mg/kg Q2W.
- mezigdomide (CC-92480) / BMS
Potent Ikaros Degradation By the Cereblon E3 Ligase Modulator CC-92480 Is Effective in Combination with Menin-MLL1 Inhibition in MLL1-Rearranged and NPM1-Mutant AML (GWCC - B302-B303, Level 3) - Nov 5, 2021 - Abstract #ASH2021ASH_1511;
In two of these experiments CC-92480 was also compared to lenalidomide and increased survival by 23.4% (p < 0.0005) and 28.1% (p < 0.05). In summary, the preclinical activity of CC-92480 in MLL1 -r and NPM1c AML models, particularly in combination with Menin-MLL1 inhibition, supports translation of this compound or a similarly potent, Ikaros-degrading CELMoD into clinical trials for these molecular subtypes of AML.
- | Journal: LCL161 interacts synergystically with panobinostat in multiple myeloma cells through non-canonical NF-κB- and caspase-8-dependent mechanisms. (Pubmed Central) - Nov 4, 2021
Similar interactions were observed with other histone deacetylase inhibitors (MS-275) or inhibitors of apoptosis protein antagonists (birinapant)...Notably, this regimen overcomes various forms of resistance, is active against primary MM cells, and displays significant in vivo activity. This strategy warrants further consideration in MM.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal: MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. (Pubmed Central) - Nov 4, 2021
MS-275 inhibited in vivo growth of RH30 cells and completely prevented the growth of RT-unresponsive RH30 xenografts when combined with radiation. Thus, MS-275 could be considered as a radio-sensitizing agent for the treatment of intrinsically radio-resistant PAX3-FOXO1 RMS.
- || entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Clinical, Journal, Checkpoint inhibition: Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. (Pubmed Central) - Oct 31, 2021
assess whether the HDAC inhibitor entinostat can enhance anti-PD-1 treatment in a bladder cancer model...In addition, the authors showed that HDAC inhibition augmented tumor neoantigen presentation, resulting in the immune editing of tumor antigens. This study highlights a mechanism by which epigenetic modifier agents can synergize with immune-checkpoint blockade for enhanced and long-lasting antitumor activity.
- | bintrafusp alfa (M7824) / EMD Serono, Kadcyla (ado-trastuzumab emtansine) / Roche, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov) - Oct 27, 2021
P1b, N=1, Completed, Sponsor: National Cancer Institute (NCI)
This study highlights a mechanism by which epigenetic modifier agents can synergize with immune-checkpoint blockade for enhanced and long-lasting antitumor activity. Suspended --> Completed | N=65 --> 1 | Trial completion date: Jan 2024 --> Oct 2021 | Trial primary completion date: Jan 2024 --> Oct 2021
- ||| haloperidol / Generic mfg.
Preclinical, Journal, Adverse events, Epigenetic controller: Dose Effects of Histone Deacetylase Inhibitor Tacedinaline (CI-994) on Antipsychotic Haloperidol-Induced Motor and Memory Side Effects in Aged Mice. (Pubmed Central) - Oct 27, 2021
Our results suggest CI-994 can reduce HAL-induced motor and memory side effects in aged mice. These effects may act through an increase of acetylation at the Drd2 promoter, thereby restoring D2R expression and improving antipsychotic drug action.
- paclitaxel / Generic mfg.
Relieving immune suppressive pathways in breast cancer to improve outcomes (Stars at Night Ballroom 1&2) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1510;
Therapies targeting myeloid-mediated T cell suppression, in combination with PTX and αPD-1 mAb, results in tumor regression, but long-term T cell memory is limited. Durable long term anti-tumor T cell memory is instead achieved following addition of entinostat-induced epigenetic reprogramming.
- || birinapant (TL 32711) / Medivir
Clinical, Journal: Birinapant Enhances Gemcitabine's Anti-tumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. (Pubmed Central) - Oct 22, 2021
Birinapant significantly enhanced the anti-tumor activity of gemcitabine in TNBC both in vitro and in xenograft mouse models through activation of the intrinsic apoptosis pathway via degradation of cIAP2 and XIAP, leading to apoptotic cell death. Our findings demonstrate the therapeutic potential of birinapant to enhance the anti-tumor efficacy of gemcitabine in TNBC by targeting the IAP family of proteins.
- | bintrafusp alfa (M7824) / EMD Serono, Kadcyla (ado-trastuzumab emtansine) / Roche, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial suspension, Metastases: BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov) - Oct 19, 2021
P1b, N=65, Suspended, Sponsor: National Cancer Institute (NCI)
Our findings demonstrate the therapeutic potential of birinapant to enhance the anti-tumor efficacy of gemcitabine in TNBC by targeting the IAP family of proteins. Recruiting --> Suspended
- | bintrafusp alfa (M7824) / EMD Serono, PDS01ADC / PDS Biotech, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial suspension, Metastases: A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (clinicaltrials.gov) - Oct 19, 2021
P1/2, N=70, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Suspended
- | mocetinostat (MGCD0103) / Mirati, Otsuka, Farydak (panobinostat) / Novartis, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal, Epigenetic controller: Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [In]In-DOTATATE Uptake in NET Cells. (Pubmed Central) - Oct 14, 2021
In addition to increasing SSTR2 expression levels, VPA enhanced the radiosensitivity of all cell lines. In conclusion, HDACi treatment increased SSTR2 expression, and radiosensitivity was also enhanced upon VPA treatment.
- || mocetinostat (MGCD0103) / Mirati, Otsuka, Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Clinical, Journal: Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. (Pubmed Central) - Oct 13, 2021
The IFD and MD results cooperatively confirmed the interactions of the promising selected hits with critical residues within HDAC1 active site. In summary, the presented computational approach can provide a set of guidelines for the further development of improved benzamide-based derivatives targeting HDAC1 isoform.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
#KyowaKirin Announces Discontinuation for Developing #KHK2375 (#Entinostat) https://t.co/FHlWYcVT9B (Twitter) - Oct 13, 2021
- entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_8;
P3
Entinostat and exemestane combination was generally tolerated and can offer meaningful clinical benefit in these patients with unmet medical need. This phase III trial was sponsored by Taizhou EOC Pharma Co., Ltd..
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
Preclinical, Journal, IO biomarker, Epigenetic controller: Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis. (Pubmed Central) - Oct 9, 2021
Functionally, Chidamide inhibits cell proliferation and promotes apoptosis through miR-34a/Bcl-2. Chidamide exerts its anticancer effect via the HDAC-mediated miR-34a/Bcl-2 axis, providing potential targets for APL therapy.
- | RGFP966 / BioMarin, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma, quisinostat (JNJ 26481585) / J&J, ChemRar
Journal: CaMKII exacerbates heart failure progression by activating class I HDACs. (Pubmed Central) - Oct 9, 2021
CaMKII activates class I HDACs in heart failure, which may be a central mechanism for heart failure progression. Selective class I HDACs inhibition may be a novel therapeutic avenue to alleviate CaMKII hyperactivity induced cardiac dysfunction.
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Trial completion date, Epigenetic controller: Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Oct 7, 2021
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Selective class I HDACs inhibition may be a novel therapeutic avenue to alleviate CaMKII hyperactivity induced cardiac dysfunction. Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Sep 2021
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Trial primary completion date: Entinostat Neuroendocrine (NE) Tumor (clinicaltrials.gov) - Oct 7, 2021
P2, N=40, Recruiting, Sponsor: Antonio Fojo
Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Sep 2021 Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Dec 2021
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Preclinical, Journal: MS275 reduces seizure-induced brain damage in developing rats by regulating p38 MAPK signaling pathways and epigenetic modification. (Pubmed Central) - Oct 6, 2021
Furthermore, MS275 was found to inhibit the expression of p38 by increasing histone H3 and H4 acetylation and decreasing histone H3 and H4 methylation. This study thereby demonstrates that HDACi MS275 can reduce the inflammatory response associated with seizure-induced brain injury through inhibiting the p38 MAPK signaling pathway and p38 gene expression.
- | Inlyta (axitinib) / Pfizer
Journal, PD(L)-1 Biomarker, IO biomarker: Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells. (Pubmed Central) - Oct 5, 2021
In vivo, axitinib and the HDAC inhibitor entinostat interacted to significantly reduce tumor growth. Collectively our findings support the exploration of axitinib and HDAC inhibitors being developed as a novel sarcoma therapy.
- || Keytruda (pembrolizumab) / Merck (MSD), entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Clinical, P2 data, Clinical Trial,Phase II, Journal: The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. (Pubmed Central) - Oct 3, 2021
P2
In conclusion, HDAC inhibition and anti-PD1 immunotherapy results in durable responses in a subset of patients with metastatic UM.Trial registration ClinicalTrials.gov registration number: NCT02697630 (registered 3 March 2016). EudraCT registration number: 2016-002114-50.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal, Epigenetic controller: Visible light-controlled carbon monoxide delivery combined with the inhibitory activity of histone deacetylases from a manganese complex for an enhanced antitumor therapy. (Pubmed Central) - Oct 2, 2021
Consequently, with a combination of CO delivery and HDAC inhibitory activity, [MnBr(CO)(APIPB)] showed a remarkably enhanced antitumor effect on HeLa cells (IC = 3.2 μM) under visible light irradiation. Therefore, this approach shows potential for the development of medicinal metal complexes for combined antitumor therapies.
- Opdivo (nivolumab) / Ono Pharma, BMS
Monitoring the impact of MDSC targeting drugs in combination with nivolumab on activation and proliferation of tumor resident effector immune cells in patient-derived 3D-EXplore platform (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_1029;
Conclusions Our data demonstrated that the ex vivo 3D-Explore is a clinically relevant platform to identify combination of immunotherapy agents capable of overcoming the unique suppressive environment developed by an individual tumor. Furthermore, the 3D-EXplore platform provides unique insight into the intact tumor immune microenvironment to develop therapeutic strategies to overcome immunosuppressive effects of MDSCs to improve the efficacy of immunotherapeutic agents in cancer.
- M-9241 / EMD Serono, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
NHS-IL12 plus Entinostat combination effectively targets anti-PD-1/PD-L1 checkpoint resistant murine tumors harboring MHC Class I and antigen processing machinery deficiency (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_493;
A biomarker signature of the mechanism involved in these studies is associated with patients‘ overall survival across multiple tumor types. Conclusions Our findings provide a rationale for combining NHS-IL12 with Entinostat in the clinical setting for patients unresponsive to ICB.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal: HDAC1-Smad3-mSin3Acomplex is required for Smad3-induced transcriptional inhibition of hepatocyte growth factor receptor in human lung cancers. (Pubmed Central) - Oct 1, 2021
These results demonstrate that Smad3-induced inhibition of c-Met transcription depends on of a functional transcriptional regulatory complex that includes Smad3, mSin3A and HDAC1 at the c-Met promoter. Collectively, our findings reveal a new regulatory mechanism of c-Met signaling, and suggest a potential molecular target for the development of anticancer drugs.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma, saracatinib (AZD0530) / AstraZeneca
Journal: Prediction and identification of synergistic compound combinations against pancreatic cancer cells. (Pubmed Central) - Sep 30, 2021
Examples of highly synergistic in vitro validated compound pairs include gemcitabine combined with Entinostat, thioridazine, loperamide, scriptaid and Saracatinib. Hence, the computational approach presented here was able to identify synergistic compound combinations against pancreatic cancer cells.
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Tecentriq (atezolizumab) / Roche
Trial suspension, Combination therapy: Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread (clinicaltrials.gov) - Sep 30, 2021
P1, N=36, Suspended, Sponsor: National Cancer Institute (NCI)
Hence, the computational approach presented here was able to identify synergistic compound combinations against pancreatic cancer cells. Recruiting --> Suspended
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Preclinical, Journal: Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia. (Pubmed Central) - Sep 29, 2021
Our findings indicate that single treatment with MS-275 and resveratrol can reduce stroke-mediated brain injury and inflammation observed 2 days after the pMCAO and put the rational to test repeated administration of the drugs. The anti-inflammatory property of MS-275 and resveratrol combination can be ascribed to both primary direct inhibition of microglia/macrophage activation and secondary glial/macrophages inhibition mediated by neuroprotection.
- ||||| axatilamab (SNDX-6352) / Syndax Pharma
Clinical: Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases https://t.co/8TTkIhupBa (Twitter) - Sep 28, 2021
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal, Epigenetic controller: Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS-275. (Pubmed Central) - Sep 26, 2021
The anti-inflammatory property of MS-275 and resveratrol combination can be ascribed to both primary direct inhibition of microglia/macrophage activation and secondary glial/macrophages inhibition mediated by neuroprotection. These findings identify class I-HDAC inhibition as a potential novel strategy to prevent disease promoting foam cell formation in CNS inflammation.
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal, Combination therapy: Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. (Pubmed Central) - Sep 24, 2021
Biomarker signature of favourable overall survival in multiple human tumor types shows close resemblance to the immune pattern generated by Entinostat/NHS-rmIL12 combination therapy. Collectively, these findings provide a rationale for combining NHS-IL12 with Entinostat in the clinical setting.
- | ZEN-3694 / Zenith Capital Corp, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
New P1/2 trial, Metastases: Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas (clinicaltrials.gov) - Sep 23, 2021
P1/2, N=30, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | doxorubicin hydrochloride / Generic mfg.
Journal: The protective effect of beta-hydroxybutyric acid on renal glomerular epithelial cells in adriamycin-induced injury. (Pubmed Central) - Sep 21, 2021
In contrast, anacardic acid, a selective inhibitor of acetyltransferase, decreases the acetylation of nephrin, WT-1, and GSK3β and mitigates the podocyte protective effects of BHB. Taken together, BHB attenuates adriamycin-elicited glomerular epithelial cell injury, at least in part, by inhibiting the deacetylation of the key molecules implicated in glomerular injury.
- |||| entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Clinical: Endocrine Therapy Plus Entinostat or Placebo in HR+ Advanced #BreastCancer Comment by Reshma L. Mahtani DO - @DrReshmaMahtani https://t.co/b5hiDtlssm (Twitter) - Sep 17, 2021